Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedFeb 05, 2026
DataAggregated Company Financials
Companies21
  • 7D-16.1%
  • 3M-1.5%
  • 1Y-44.5%
  • YTD-6.6%

Over the last 7 days, the Healthcare industry has dropped 16%, driven by Novo Nordisk declining 20%. Overall the industry is down 44% in 12 months. As for the next few years, earnings are expected to grow by 3.9% per annum.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 05 Feb 2026DKK 1.8tDKK 447.6bDKK 135.2b17.3x13.5x4.1x
Sat, 03 Jan 2026DKK 2.0tDKK 453.8bDKK 136.9b17x14.3x4.3x
Mon, 01 Dec 2025DKK 1.9tDKK 454.1bDKK 137.0b17.5x14x4.2x
Wed, 29 Oct 2025DKK 2.0tDKK 447.7bDKK 141.8b18.1x13.9x4.4x
Fri, 26 Sep 2025DKK 2.1tDKK 447.5bDKK 141.7b18.1x14.7x4.7x
Sun, 24 Aug 2025DKK 2.1tDKK 447.3bDKK 141.7b24.9x14.8x4.7x
Tue, 22 Jul 2025DKK 2.3tDKK 423.1bDKK 124.5b29.7x18.4x5.4x
Thu, 19 Jun 2025DKK 2.6tDKK 423.6bDKK 124.6b30.4x20.9x6.1x
Sat, 17 May 2025DKK 2.4tDKK 424.4bDKK 125.1b23.5x18.8x5.5x
Mon, 14 Apr 2025DKK 2.3tDKK 409.3bDKK 121.3b21.9x19x5.6x
Wed, 12 Mar 2025DKK 2.8tDKK 409.5bDKK 121.3b25.1x23.4x6.9x
Fri, 07 Feb 2025DKK 3.4tDKK 408.2bDKK 118.3b28.3x28.3x8.2x
Sun, 05 Jan 2025DKK 3.4tDKK 387.5bDKK 111.3b30.3x30.3x8.7x
Tue, 03 Dec 2024DKK 4.0tDKK 387.4bDKK 111.3b31.5x36x10.3x
Thu, 31 Oct 2024DKK 4.0tDKK 372.2bDKK 107.2b33.6x37.2x10.7x
Sat, 28 Sep 2024DKK 4.1tDKK 371.9bDKK 107.1b36.5x38.4x11.1x
Mon, 26 Aug 2024DKK 4.7tDKK 371.6bDKK 107.0b36.6x43.6x12.6x
Wed, 24 Jul 2024DKK 4.7tDKK 355.3bDKK 106.2b36.6x44.1x13.2x
Fri, 21 Jun 2024DKK 5.0tDKK 355.3bDKK 106.2b34.6x46.9x14x
Sun, 19 May 2024DKK 4.6tDKK 355.3bDKK 106.2b37.8x43.2x12.9x
Tue, 16 Apr 2024DKK 4.5tDKK 341.3bDKK 99.7b33.8x45.1x13.2x
Thu, 14 Mar 2024DKK 4.7tDKK 341.2bDKK 99.6b39.7x46.7x13.6x
Sat, 10 Feb 2024DKK 4.3tDKK 340.0bDKK 98.5b33.1x43.4x12.6x
Mon, 08 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.2x41.7x11.7x
Wed, 06 Dec 2023DKK 3.6tDKK 320.5bDKK 90.0b33.4x39.7x11.2x
Fri, 03 Nov 2023DKK 3.7tDKK 318.8bDKK 90.3b28.5x40.5x11.5x
Sun, 01 Oct 2023DKK 3.4tDKK 305.5bDKK 82.2b33.6x41.4x11.1x
Tue, 29 Aug 2023DKK 3.4tDKK 305.2bDKK 82.1b35.8x41.8x11.2x
Thu, 27 Jul 2023DKK 2.9tDKK 287.1bDKK 75.5b36.9x38.5x10.1x
Sat, 24 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b39.9x39.7x10.4x
Mon, 22 May 2023DKK 3.2tDKK 287.1bDKK 75.5b41x41.9x11x
Wed, 19 Apr 2023DKK 3.2tDKK 272.6bDKK 68.5b44x46.4x11.7x
Fri, 17 Mar 2023DKK 2.7tDKK 292.6bDKK 69.2b37.7x39.4x9.3x
Sun, 12 Feb 2023DKK 2.7tDKK 289.4bDKK 68.9b39.3x39.6x9.4x
Price to Earnings Ratio

39.6x


Total Market Cap: DKK 2.7tTotal Earnings: DKK 68.9bTotal Revenue: DKK 289.4bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 33.3x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 13.5x which is lower than its 3-year average PE of 33.3x.
  • The 3-year average PS ratio of 9.4x is higher than the industry's current PS ratio of 4.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 25% per year over the last three years.
  • Revenues for these companies have grown 16% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-6.43%
Healthcare-16.12%
Healthcare Services0%0
Biotech-0.59%
Medical Equipment-1.95%
Healthtech-2.24%
Life Sciences-6.73%
Pharma-19.33%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 320x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 103% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 20% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
COLO B ColoplastDKK 540.201.3%
+DKK 1.5b		-32.5%PE33.5x
ZEAL Zealand PharmaDKK 430.305.1%
+DKK 1.5b		-41.6%PE4.6x
ALK B ALK-AbellóDKK 216.801.7%
+DKK 796.3m		36.4%PE43.6x
AMBU B AmbuDKK 87.852.9%
+DKK 612.5m		-34.4%PE38.3x
BAVA Bavarian NordicDKK 196.650.9%
+DKK 105.2m		13.7%PE6.2x

Latest News

HLUN B
DKK 38.82
H. Lundbeck
7D
-10.5%
1Y
-13.5%
NOVO B
DKK 304.65
Novo Nordisk
7D
-20.1%
1Y
-50.8%
DEMANT
DKK 194.40
Demant
7D
-12.2%
1Y
-26.2%
EMBLA
DKK 30.60
Embla Medical hf
7D
-3.5%
1Y
-7.3%
PEG
DKK 0.10
Pharma Equity Group
7D
9.5%
1Y
-34.2%
BAVA
DKK 196.65
Bavarian Nordic
7D
0.9%
1Y
13.7%

BAVA: Latin America Vaccine Deal Will Support Future Earnings Upside

Analysts have nudged their price target on Bavarian Nordic higher to €265, up from €260, citing updated assumptions on discount rates, revenue expectations, profit margins and forward P/E multiples. What's in the News Bavarian Nordic signed an agreement with Eurofarma, giving Eurofarma exclusive rights to sell and distribute the chikungunya vaccine CHIKV VLP, marketed as VIMKUNYA, in Brazil, along with a right of first refusal for future Latin American opportunities, on a transfer price and royalty basis with no upfront or milestone payments (Key Developments).
GMAB
DKK 2,007.00
Genmab
7D
-2.0%
1Y
43.1%

GMAB: Phase 3 Data, AI Adoption And 2026 Readout Will Shape Outlook

Genmab’s analyst fair value estimate has moved modestly higher to DKK 2,188.94. Analysts point to updated assumptions around slightly lower discount rates, adjusted revenue growth and profit margin expectations, and a recalibrated future P/E multiple as the key drivers behind the refreshed price targets.
ALK B
DKK 216.80
ALK-Abelló
7D
1.7%
1Y
36.4%
AMBU B
DKK 87.85
Ambu
7D
2.9%
1Y
-34.4%

AMBU B: Share Repurchases And Dividend Policy Will Support Future Upside

Analysts have slightly reduced their price target on Ambu, citing modest revisions to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Together, these changes support a more cautious yet still constructive view on the shares.
ZEAL
DKK 430.30
Zealand Pharma
7D
5.1%
1Y
-41.6%

ZEAL: Metabolic Collaboration Will Support Future Upside As Margins Strengthen

Analysts see Zealand Pharma’s fair value estimate broadly unchanged at around €745.93 per share. The updated target reflects slightly firmer profit margin assumptions at 26.94%, a modestly smaller 36.49% revenue decline, and a lower forward P/E of 94.77x, partly offset by a marginally higher 5.17% discount rate.
COLO B
DKK 540.20
Coloplast
7D
1.3%
1Y
-32.5%

Coloplast A/S' (CPH:COLO B) P/E Is On The Mark

Jan 25
Coloplast A/S' (CPH:COLO B) P/E Is On The Mark
NNIT
DKK 44.55
NNIT
7D
-2.2%
1Y
-50.4%

NNIT: Higher Margins And CEO Transition Will Support Future Upside Potential

Analysts have trimmed their price target on NNIT from DKK 75 to about DKK 62.50, as updated assumptions reflect a higher discount rate, more moderate revenue growth, stronger profit margins, and a lower future P/E multiple. What's in the News CEO Pär Fors has decided to leave NNIT for personal family reasons and will remain in the role until the end of July 2026 or until a new CEO is appointed, whichever comes first (Key Developments).
GUBRA
DKK 439.80
Gubra
7D
-2.6%
1Y
-27.2%
VIRO
DKK 13.00
ViroGates
7D
17.1%
1Y
16.1%
CHEMM
DKK 579.50
ChemoMetec
7D
-9.5%
1Y
6.5%